{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:40:02Z","timestamp":1741185602582,"version":"3.38.0"},"reference-count":55,"publisher":"JLE","issue":"3","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.nephro.2006.04.001","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T14:57:11Z","timestamp":1148309831000},"page":"140-151","source":"Crossref","is-referenced-by-count":1,"title":["Manifestations r\u00e9nales des\u00a0maladies auto-immunes syst\u00e9miques\u00a0: diagnostic et\u00a0traitement"],"prefix":"10.1684","volume":"2","author":[{"given":"Christopher Anthony","family":"O\u2019Callaghan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2006.04.001_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. The European Working Party on Systemic Lupus Erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2006.04.001_bib2","series-title":"Oxford textbook of clinical nephrology","first-page":"2709","article-title":"Rheumatology and the kidney","author":"Cameron","year":"1997"},{"key":"10.1016\/j.nephro.2006.04.001_bib3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ki.1984.75","article-title":"Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome","volume":"25","author":"Austin","year":"1984","journal-title":"Kidney Int."},{"key":"10.1016\/j.nephro.2006.04.001_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00005792-197711000-00004","article-title":"Lupus nephropathy without clinical renal involvement","volume":"56","author":"Mahajan","year":"1977","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2006.04.001_bib5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0002-9343(84)90350-4","article-title":"Course of renal pathology in patients with systemic lupus erythematosus","volume":"77","author":"Lee","year":"1984","journal-title":"Am. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib6","first-page":"147","article-title":"Cyclosporine treatment of lupus membranous nephropathy","volume":"42","author":"Radhakrishnan","year":"1994","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.nephro.2006.04.001_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0307-742X(21)00212-5","article-title":"Pulse methylprednisolone in SLE","volume":"8","author":"Kimberly","year":"1982","journal-title":"Clin. Rheum. Dis."},{"key":"10.1016\/j.nephro.2006.04.001_bib8","first-page":"263","article-title":"Long-term prognosis of diffuse lupus nephritis","volume":"28","author":"Ponticelli","year":"1987","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.nephro.2006.04.001_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2006.04.001_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-199040010-00003","article-title":"Current treatment recommendations for lupus nephritis","volume":"40","author":"Ponticelli","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.nephro.2006.04.001_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000186550","article-title":"Diffuse and focal proliferative lupus nephritis: treatment approaches and results","volume":"59","author":"Pollak","year":"1991","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2006.04.001_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled tria","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/ajkd.1998.v31.pm9469489","article-title":"Successful mycophenolate mofetil treatment of glomerular disease","volume":"31","author":"Briggs","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.nephro.2006.04.001_bib15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/ajkd.1998.v32.pm9708620","article-title":"Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide","volume":"32","author":"Glicklich","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.nephro.2006.04.001_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1681\/ASN.V104833","article-title":"Mycophenolate mofetil therapy in lupus nephritis: clinical observations","volume":"10","author":"Dooley","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.nephro.2006.04.001_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/rheumatology\/keh012","article-title":"Lupus nephritis: treatment with mycophenolate mofetil","volume":"43","author":"Kapitsinou","year":"2004","journal-title":"Rheumatology"},{"issue":"suppl1","key":"10.1016\/j.nephro.2006.04.001_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000168040","article-title":"Cyclosporin in the treatment of lupus nephritis","volume":"9","author":"Favre","year":"1989","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.nephro.2006.04.001_bib20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"326","author":"Lewis","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0049-0172(00)80018-9","article-title":"Intravenous immunoglobulin treatment of lupus nephritis","volume":"29","author":"Levy","year":"2000","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.nephro.2006.04.001_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(99)01575-5","article-title":"Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis","volume":"354","author":"Boletis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2006.04.001_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2003.10.012","article-title":"Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials","volume":"43","author":"Flanc","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.nephro.2006.04.001_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0272-6386(12)80712-8","article-title":"End-stage renal disease in systemic lupus erythematosus","volume":"21","author":"Cheigh","year":"1993","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.nephro.2006.04.001_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0002-9343(96)00074-5","article-title":"End-stage renal disease and systemic lupus erythematosus","volume":"101","author":"Mojcik","year":"1996","journal-title":"Am. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/096120339600500214","article-title":"Pharmacological intervention in antibody mediated disease","volume":"5","author":"Coutts","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.nephro.2006.04.001_bib27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/art.10763","article-title":"LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study","volume":"48","author":"Alarcon-Segovia","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nephro.2006.04.001_bib28","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1126\/science.7520604","article-title":"Treatment of murine lupus with CTLA4Ig","volume":"265","author":"Finck","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.nephro.2006.04.001_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4049\/jimmunol.171.1.489","article-title":"Short-term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB\/W F1 mice by a mechanism downstream of renal immune complex deposition","volume":"171","author":"Schiffer","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.nephro.2006.04.001_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0049-0172(95)80015-8","article-title":"Epidemiology of systemic vasculitis: changing incidence or definition?","volume":"25","author":"Watts","year":"1995","journal-title":"Semin. Arthritis Rheum."},{"issue":"suppl1","key":"10.1016\/j.nephro.2006.04.001_bib31","first-page":"6","article-title":"Report on management of renal failure in Europe, XXIII","volume":"9","author":"Geerlings","year":"1994","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.nephro.2006.04.001_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.nephro.2006.04.001_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.nephro.2006.04.001_bib34","first-page":"138","article-title":"ANCA-associated renal disease","volume":"86","author":"Gaskin","year":"1993","journal-title":"Q. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib37","series-title":"Oxford textbook of clinical nephrology","first-page":"877","article-title":"Systemic vasculitis","author":"Gaskin","year":"1997"},{"key":"10.1016\/j.nephro.2006.04.001_bib38","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.nephro.2006.04.001_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","article-title":"Cyclophosphamide therapy of severe systemic necrotizing vasculitis","volume":"301","author":"Fauci","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney Int."},{"key":"10.1016\/j.nephro.2006.04.001_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000167998","article-title":"Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis","volume":"9","author":"Bolton","year":"1989","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.nephro.2006.04.001_bib43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","article-title":"An analysis of forty-two Wegener\u2019s granulomatosis patients treated with methotrexate and prednisone","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.nephro.2006.04.001_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.qjmed.a030133","article-title":"Response to trimethoprim\/sulfamethoxazole in Wegener\u2019s granulomatosis depends on the phase of disease","volume":"89","author":"Reinhold-Keller","year":"1996","journal-title":"Q. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib45","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0140-6736(91)92797-6","article-title":"Treatment of systemic vasculitis with pooled intravenous immunoglobulin","volume":"337","author":"Jayne","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2006.04.001_bib46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Q. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib47","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/0140-6736(93)90759-A","article-title":"Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy","volume":"341","author":"Lockwood","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2006.04.001_bib48","first-page":"351","article-title":"Compassionate treatment of Wegener\u2019s granulomatosis with rabbit anti-thymocyte globulin","volume":"43","author":"Hagen","year":"1995","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.nephro.2006.04.001_bib49","series-title":"Oxford textbook of clinical nephrology","first-page":"961","article-title":"The patient with scleroderma-systemic sclerosis","author":"Black","year":"1997"},{"key":"10.1016\/j.nephro.2006.04.001_bib50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00005792-198311000-00001","article-title":"Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases","volume":"62","author":"Traub","year":"1983","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2006.04.001_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197401000-00001","article-title":"The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation","volume":"53","author":"Cannon","year":"1974","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2006.04.001_bib52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","article-title":"Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls","volume":"46","author":"D\u2019Angelo","year":"1969","journal-title":"Am. J. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.nephro.2006.04.001_bib54","first-page":"1944","article-title":"Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis","volume":"24","author":"Scorza","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.nephro.2006.04.001_bib55","first-page":"236","article-title":"Scleroderma at end stage renal disease in the United States: patient characteristics and survival","volume":"15","author":"Abbott","year":"2002","journal-title":"J. Nephrol."}],"container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725506000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725506000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2006.04.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:47:30Z","timestamp":1741182450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725506000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1769725506000460"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2006.04.001","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}